

RECEIVED  
CENTRAL FAX CENTER  
JUL 27 2006

REMARKS

Entry of this amendment and reconsideration of this application, as amended, are respectfully requested.


Pursuant to the restriction requirement, Applicants elect to prosecute the claims of Group II. As a species, Applicants elect to prosecute (N-3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1 H-indol-3-yl]-2-oxoacetamide (AWD-12-281).

Claims 1-4, 6, and 8-23 are believed to read on this species.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-HUBR-1221-US. A duplicate copy of this paper is enclosed.

Respectfully submitted

FULBRIGHT & JAWORSKI L.L.P.

By   
James R. Crawford  
Reg. No. 39,155

666 Fifth Avenue  
New York, New York 10103  
(212) 318-3148